A study to compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir

Trial Profile

A study to compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Raltegravir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2017 New trial record
    • 24 Aug 2017 Results published in the AIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top